[{"Assets_0_Q3_USD":662337000.0,"CommonStockSharesOutstanding_0_Q3_shares":21094836.0,"EarningsPerShareBasic_1_Q3_USD":0.4,"EarningsPerShareBasic_3_Q3_USD":0.93,"EarningsPerShareDiluted_1_Q3_USD":0.36,"EarningsPerShareDiluted_3_Q3_USD":0.84,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":62258000.0,"NetIncomeLoss_1_Q3_USD":8426000.0,"NetIncomeLoss_3_Q3_USD":19566000.0,"StockholdersEquity_0_Q3_USD":403166000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":23551245.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":23261857.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":21071000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":21007000.0,"Ticker":"LGND","CIK":"886163","name":"LIGAND PHARMACEUTICALS INC","OfficialName":"Ligand Pharmaceuticals Incorporated Common Stock","form":"10-Q","period":"20170930","fy":"2017.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1738856427.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20171109"}]